<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d234" origId="Nisoldipine"><sentence id="DrugDDI.d234.s0" origId="s0" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily."><entity id="DrugDDI.d234.s0.e0" origId="s0.p5" charOffset="40-51" type="drug" text="nisoldipine"/><entity id="DrugDDI.d234.s0.e1" origId="s0.p9" charOffset="100-117" type="drug" text="cimetidine 400 mg"/><pair id="DrugDDI.d234.s0.p0" e1="DrugDDI.d234.s0.e0" e2="DrugDDI.d234.s0.e1" interaction="?"/></sentence><sentence id="DrugDDI.d234.s1" origId="s1" text="Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %)."><entity id="DrugDDI.d234.s1.e0" origId="s1.p10" charOffset="0-17" type="drug" text="Ranitidine 150 mg"/><entity id="DrugDDI.d234.s1.e1" origId="s1.p15" charOffset="66-77" type="drug" text="nisoldipine"/><pair id="DrugDDI.d234.s1.p0" e1="DrugDDI.d234.s1.e0" e2="DrugDDI.d234.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d234.s2" origId="s2" text="No pharmacodynamic effects of either histamine H2 receptor antagonist were observed."><entity id="DrugDDI.d234.s2.e0" origId="s2.p25" charOffset="37-70" type="drug" text="histamine H2 receptor antagonist"/></sentence><sentence id="DrugDDI.d234.s3" origId="s3" text="Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels."><entity id="DrugDDI.d234.s3.e0" origId="s3.p29" charOffset="20-29" type="drug" text="phenytoin"/><entity id="DrugDDI.d234.s3.e1" origId="s3.p30" charOffset="41-46" type="drug" text="SULAR"/><entity id="DrugDDI.d234.s3.e2" origId="s3.p33" charOffset="89-100" type="drug" text="nisoldipine"/><pair id="DrugDDI.d234.s3.p0" e1="DrugDDI.d234.s3.e0" e2="DrugDDI.d234.s3.e1" interaction="?"/><pair id="DrugDDI.d234.s3.p1" e1="DrugDDI.d234.s3.e0" e2="DrugDDI.d234.s3.e2" interaction="?"/><pair id="DrugDDI.d234.s3.p2" e1="DrugDDI.d234.s3.e1" e2="DrugDDI.d234.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d234.s4" origId="s4" text="Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered."><entity id="DrugDDI.d234.s4.e0" origId="s4.p36" charOffset="20-25" type="drug" text="SULAR"/><entity id="DrugDDI.d234.s4.e1" origId="s4.p37" charOffset="31-40" type="drug" text="phenytoin"/><entity id="DrugDDI.d234.s4.e2" origId="s4.p39" charOffset="54-60" type="drug" text="CYP3A4"/><entity id="DrugDDI.d234.s4.e3" origId="s4.p44" charOffset="103-119" type="drug" text="antihypertensive"/><pair id="DrugDDI.d234.s4.p0" e1="DrugDDI.d234.s4.e0" e2="DrugDDI.d234.s4.e1" interaction="?"/><pair id="DrugDDI.d234.s4.p1" e1="DrugDDI.d234.s4.e0" e2="DrugDDI.d234.s4.e2" interaction="?"/><pair id="DrugDDI.d234.s4.p2" e1="DrugDDI.d234.s4.e0" e2="DrugDDI.d234.s4.e3" interaction="?"/><pair id="DrugDDI.d234.s4.p3" e1="DrugDDI.d234.s4.e1" e2="DrugDDI.d234.s4.e2" interaction="?"/><pair id="DrugDDI.d234.s4.p4" e1="DrugDDI.d234.s4.e1" e2="DrugDDI.d234.s4.e3" interaction="?"/><pair id="DrugDDI.d234.s4.p5" e1="DrugDDI.d234.s4.e2" e2="DrugDDI.d234.s4.e3" interaction="?"/></sentence><sentence id="DrugDDI.d234.s5" origId="s5" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant."><entity id="DrugDDI.d234.s5.e0" origId="s5.p49" charOffset="37-48" type="drug" text="nisoldipine"/><entity id="DrugDDI.d234.s5.e1" origId="s5.p51" charOffset="53-67" type="drug" text="beta-blockers"/><entity id="DrugDDI.d234.s5.e2" origId="s5.p53" charOffset="68-76" type="drug" text="atenolol"/><entity id="DrugDDI.d234.s5.e3" origId="s5.p54" charOffset="78-89" type="drug" text="propranolol"/><pair id="DrugDDI.d234.s5.p0" e1="DrugDDI.d234.s5.e0" e2="DrugDDI.d234.s5.e1" interaction="?"/><pair id="DrugDDI.d234.s5.p1" e1="DrugDDI.d234.s5.e0" e2="DrugDDI.d234.s5.e2" interaction="?"/><pair id="DrugDDI.d234.s5.p2" e1="DrugDDI.d234.s5.e0" e2="DrugDDI.d234.s5.e3" interaction="?"/><pair id="DrugDDI.d234.s5.p3" e1="DrugDDI.d234.s5.e1" e2="DrugDDI.d234.s5.e2" interaction="?"/><pair id="DrugDDI.d234.s5.p4" e1="DrugDDI.d234.s5.e1" e2="DrugDDI.d234.s5.e3" interaction="?"/><pair id="DrugDDI.d234.s5.p5" e1="DrugDDI.d234.s5.e2" e2="DrugDDI.d234.s5.e3" interaction="?"/></sentence><sentence id="DrugDDI.d234.s6" origId="s6" text="Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine."><entity id="DrugDDI.d234.s6.e0" origId="s6.p60" charOffset="0-11" type="drug" text="Propranolol"/><entity id="DrugDDI.d234.s6.e1" origId="s6.p65" charOffset="93-104" type="drug" text="nisoldipine"/><pair id="DrugDDI.d234.s6.p0" e1="DrugDDI.d234.s6.e0" e2="DrugDDI.d234.s6.e1" interaction="?"/></sentence><sentence id="DrugDDI.d234.s7" origId="s7" text="The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy."><entity id="DrugDDI.d234.s7.e0" origId="s7.p67" charOffset="29-34" type="drug" text="SULAR"/><entity id="DrugDDI.d234.s7.e1" origId="s7.p73" charOffset="71-79" type="drug" text="atenolol"/><entity id="DrugDDI.d234.s7.e2" origId="s7.p76" charOffset="109-125" type="drug" text="antihypertensive"/><pair id="DrugDDI.d234.s7.p0" e1="DrugDDI.d234.s7.e0" e2="DrugDDI.d234.s7.e1" interaction="?"/><pair id="DrugDDI.d234.s7.p1" e1="DrugDDI.d234.s7.e0" e2="DrugDDI.d234.s7.e2" interaction="?"/><pair id="DrugDDI.d234.s7.p2" e1="DrugDDI.d234.s7.e1" e2="DrugDDI.d234.s7.e2" interaction="?"/></sentence><sentence id="DrugDDI.d234.s8" origId="s8" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration."><entity id="DrugDDI.d234.s8.e0" origId="s8.p77" charOffset="0-9" type="drug" text="Quinidine"/><entity id="DrugDDI.d234.s8.e1" origId="s8.p78" charOffset="20-23" type="drug" text="bid"/><entity id="DrugDDI.d234.s8.e2" origId="s8.p84" charOffset="63-74" type="drug" text="nisoldipine"/><pair id="DrugDDI.d234.s8.p0" e1="DrugDDI.d234.s8.e0" e2="DrugDDI.d234.s8.e1" interaction="?"/><pair id="DrugDDI.d234.s8.p1" e1="DrugDDI.d234.s8.e0" e2="DrugDDI.d234.s8.e2" interaction="?"/><pair id="DrugDDI.d234.s8.p2" e1="DrugDDI.d234.s8.e1" e2="DrugDDI.d234.s8.e2" interaction="?"/></sentence><sentence id="DrugDDI.d234.s9" origId="s9" text="The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%."><entity id="DrugDDI.d234.s9.e0" origId="s9.p91" charOffset="60-71" type="drug" text="nisoldipine"/></sentence><sentence id="DrugDDI.d234.s10" origId="s10" text="This interaction was not accompanied by ECG changes and its clinical significance is not known."/><sentence id="DrugDDI.d234.s11" origId="s11" text="No significant interactions were found between nisoldipine and warfarin or digoxin."><entity id="DrugDDI.d234.s11.e0" origId="s11.p106" charOffset="47-58" type="drug" text="nisoldipine"/><entity id="DrugDDI.d234.s11.e1" origId="s11.p108" charOffset="63-71" type="drug" text="warfarin"/><entity id="DrugDDI.d234.s11.e2" origId="s11.p110" charOffset="75-82" type="drug" text="digoxin"/><pair id="DrugDDI.d234.s11.p0" e1="DrugDDI.d234.s11.e0" e2="DrugDDI.d234.s11.e1" interaction="?"/><pair id="DrugDDI.d234.s11.p1" e1="DrugDDI.d234.s11.e0" e2="DrugDDI.d234.s11.e2" interaction="?"/><pair id="DrugDDI.d234.s11.p2" e1="DrugDDI.d234.s11.e1" e2="DrugDDI.d234.s11.e2" interaction="?"/></sentence></document>